Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087883 | 0.81 | DAO (0.37) | KMO | |
| SCHEMBL1097565 | 0.78 | GAA (0.31) | — | |
| SCHEMBL823939 | 0.78 | — | — | |
| SCHEMBL1097452 | 0.77 | DYRK1A (0.36) | KMO | |
| SCHEMBL1097916 | 0.76 | KMO (0.36) | KMO | |
| SCHEMBL1108281 | 0.76 | KMO (0.36) | KMO | |
| SCHEMBL1099147 | 0.73 | GAA (0.33) | — | |
| SCHEMBL823895 | 0.73 | KMO (0.41) | KMO | |
| SCHEMBL1097124 | 0.68 | KMO (0.36) | KMO | |
| SCHEMBL19766402 | 0.63 | KMO (0.39) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | SOBI, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| EP-1951729-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*Bio Pte Ltd (SG) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | KMO 1161/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | KMO 1161/4885 |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | KMO 1161/4885 |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | KMO 1161/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | KMO 1161/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | KMO 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.